A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer (Q33504516)

27 July 2017

A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer (English)

1 reference

27 July 2017

1 reference

1

E E Vokes

1 reference

27 July 2017

6

M J Ratain

1 reference

27 July 2017

11

H M Golomb

1 reference

27 July 2017

R H Ansari

2

1 reference

27 July 2017

G A Masters

3

1 reference

27 July 2017

P C Hoffman

4

1 reference

27 July 2017

A Klepsch

5

1 reference

27 July 2017

D F Sciortino

7

1 reference

27 July 2017

T E Lad

8

1 reference

27 July 2017

S Krauss

9

1 reference

27 July 2017

P A Fishkin

10

1 reference

27 July 2017

1 October 1998

1 reference

27 July 2017

1 reference

27 July 2017

9

1 reference

27 July 2017

10

1 reference

27 July 2017

1085-1090

1 reference

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

27 July 2017

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008432729754

7 January 2021

https://api.crossref.org/works/10.1023%2FA%3A1008432729754

1 reference

7 January 2021

Topoisomerase I inhibitors: review and update

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008432729754

7 January 2021

Camptothecin and its analogs. An overview of their potential in cancer therapeutics

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008432729754

7 January 2021

Phase I and pharmacokinetic trial of weekly CPT-11

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008432729754

7 January 2021

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008432729754

7 January 2021

Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008432729754

7 January 2021

Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008432729754

7 January 2021

Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008432729754

7 January 2021

Phase II study of topotecan in metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008432729754

7 January 2021

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008432729754

7 January 2021

Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008432729754

7 January 2021

Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008432729754

7 January 2021

9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008432729754

7 January 2021

Non-small-cell lung cancer. Toward the next plateau

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008432729754

7 January 2021

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008432729754

7 January 2021

Identifiers

DOI

10.1023/A:1008432729754

1 reference

27 July 2017

1 reference